A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors

Phase 1

Active, not recruiting

• Conditions: Solid Tumors
• Interventions: Drug: Eciskafusp Alfa; Drug: Atezolizumab

• Registration Number: NCT04303858
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

This is an entry-into-human study and will assess the effects of eciskafusp alfa (RO7284755) as a single agent and in combination with atezolizumab in adult participants with solid tumors considered responsive to checkpoint inhibition blockade. The maximum duration in the study for each participant will be up to 28 months.

Detailed Description

The study consists of three parts: dose-escalation of eciskafusp alfa as a single agent (Part 1), dose-escalation of eciskafusp alfa in combination with atezolizumab (Part 2), and extension of eciskafusp alfa as a single agent and/or in combination with atezolizumab (Part 3).

Study Timeline

• Study First Submitted: 2020-03-09
• Study First Submitted QC: 2020-03-09
• Study First Posted: 2020-03-11
• Study Start: 2020-05-04
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-03
• Last Update Posted: 2025-03-05
• Primary Completion: 2026-11-07
• Study Completion: 2027-05-27

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 189

Inclusion Criteria

• Locally advanced/unresectable or metastatic disease
• No standard of care (SoC) (approved) treatments are available for the participant, or the participant cannot tolerate such treatments
• Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
• Eastern Cooperative Oncology Group Performance Status 0 to 1
• Life expectancy of >=12 weeks
• Consent to provide an archival tumor tissue sample
• Adequate cardiovascular, hematological, coagulative, hepatic and renal function

Exclusion Criteria

• Rapid disease progression or suspected hyperprogression or threat to vital organs or critical anatomical sites requiring urgent alternative medical intervention
• Untreated central nervous system (CNS) metastases
• Treated asymptomatic CNS metastases
• Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for >= 2 weeks before Cycle1 Day 1 (C1D1)
• Active or history of carcinomatous meningitis/leptomeningeal disease
• Uncontrolled tumor-related pain or symptomatic hypercalcemia
• Concurrent second malignancy
• Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results
• Episode of significant cardiovascular/cerebrovascular acute disease within 28 days before study treatment administration
• Active or uncontrolled infections
• Known HIV infection
• Hepatitis B virus (HBV) or hepatitis C virus infection
• Adverse events related to any prior radiotherapy, chemotherapy, targeted therapy, CPI therapy or surgical procedure must have resolved to Grade <=1, except alopecia Grade 2 peripheral neuropathy, and hypothyroidism and/or hypopituitarism on a stable dosage of hormone replacement therapy
• Participants with bilateral pleural effusion
• Major surgery or significant traumatic injury < 28 days before study treatment administration or anticipation of the need for major surgery during study treatment
• Known allergy or hypersensitivity to any component of the formulations of the IMPs to be administered, including but not limited to hypersensitivity to Chinese hamster ovary cell products or other recombinant or humanized antibodies
• History of severe allergic anaphylactic reactions to chimeric, human or humanized antibodies, or fusion proteins
• Previous treatment with Interleukin-2 (IL-2)/Interleukin-5 (IL-15)-like cytokines. IL-2/IL-15 use as an adjunct treatment component for adoptive cell therapy is permitted. In Part 3, patients who have received adoptive cell therapy such as tumor-infiltrating lymphocytes (TIL) are excluded.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Eciskafusp Alfa as a Single Agent	Eciskafusp Alfa	Part 1: Dose-escalation of eciskafusp alfa as a single agent. eciskafusp alfa will be either an intravenous administration (IV) or subcutaneous administration (SC) in multiple-ascending doses.
Eciskafusp Alfa in Combination with Atezolizumab	Eciskafusp Alfa	Part 2: Dose-escalation of eciskafusp alfa in combination with atezolizumab.
Eciskafusp Alfa in Combination with Atezolizumab	Atezolizumab	Part 2: Dose-escalation of eciskafusp alfa in combination with atezolizumab.
Eciskafusp Alfa as a Single Agent and/or with Atezolizumab	Eciskafusp Alfa	Part 3: Extension of eciskafusp alfa as a single agent and/or in combination with atezolizumab.
Eciskafusp Alfa as a Single Agent and/or with Atezolizumab	Atezolizumab	Part 3: Extension of eciskafusp alfa as a single agent and/or in combination with atezolizumab.

Primary Outcome Measures

Name	Time	Method
Percentage of Participants with Adverse Events in Part 1 and Part 2	From randomization until end of Part 1 and Part 2 (up to approximately 1.5 months)	An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. All AE events will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Percentage of Participants with Dose-Limiting Toxicities in Part 1 and Part 2	From randomization up to day 14 (Part 1) or day 28 (Part 2)	A DLT is defined as a clinically significant AE (classified according to the NCI CTCAE version 5) or significant laboratory abnormality that occur during the DLT assessment periods, during Part 1 and Part 2 only, and is considered by the Investigator to be related to eciskafusp alfa or to the combination of eciskafusp alfa and atezolizumab. In Part 2, expected toxicities that are, in the opinion of the Investigator, entirely attributable to atezolizumab, will not be considered DLTs.
Investigator Assessed Objective Response Rate according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Part 3	From start of extension phase until disease progression, drug discontinuation, withdrawal or death (up to approximately 26 months)	Objective response rate (ORR) was defined as the percentage of participants with investigator-assessed objective response of complete response (CR) or partial response (PR). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions).
Recommended Dose for Extension (RDE) of Eciskafusp Alfa in Parts 1 and 2	From randomization up to day 14 (Part 1) or day 28 (Part 2)

Secondary Outcome Measures

Name	Time	Method
Investigator Assessed Objective Response Rate according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Parts 1 and 2	From randomization until end of Part 1 and Part 2 (up to approximately 1.5 months)	ORR was defined as the percentage of participants with investigator-assessed objective response of complete response (CR) or partial response (PR). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions).
Percentage of Participants with Adverse Events in Part 3	From start of extension phase until disease progression, drug discontinuation, withdrawal or death (up to approximately 26 months)	An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. All AE events will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Duration of Response in Part 3	From start of extension phase until disease progression, drug discontinuation, withdrawal or death (up to approximately 26 months)	Duration of response will be calculated for 'responder' participants (i.e. best \[confirmed\] overall response of CR or PR) and will be defined as the time from first occurrence of a documented response until the time of documented disease progression or death (death within 30 days from last study treatment) from any cause, whichever occurs first.
Percentage of Immune and Tumor Cells with Positive Programmed Cell Death-1 (PD-1) and Programmed Cell Death-Ligand 1 (PD-L1) Expression in the Tumor Microenvironment (TME)	Baseline
Change from Baseline in Percentage of Immune Cell Subsets	Baseline to End of Treatment (up to approximately 28 months)	Immune cells include NK, CD8, and Treg cells
Disease Control Rate in Part 3	From start of extension phase until disease progression, drug discontinuation, withdrawal or death (up to approximately 26 months)	The disease control rate was defined as proportion of participants being either responder or in 'stable disease' (SD). To classify a response as SD, measurements will have to be classified as stable (according to RECIST v1.1) at least once at a minimum of 4 weeks after study entry.
Minimum Concentration (Cmin) for Eciskafusp Alfa	Predose, C1 Days 1, 2, 3, 5, 8, 9, 10, 12, 15, 16, 17, and 19; C2 Days 1, 2, 8, 9, 10, 12, 15, and 16; C3 Days 1, 2, 3, and 8; C4 Days 1 and 2; C5 Days1, 2, and 8; and days 1 and 2 for any subsequent cycles (Up to 28 months)
Maximum Concentration (Cmax) for Eciskafusp Alfa	Predose, C1 Days 1, 2, 3, 5, 8, 9, 10, 12, 15, 16, 17, and 19; C2 Days 1, 2, 8, 9, 10, 12, 15, and 16; C3 Days 1, 2, 3, and 8; C4 Days 1 and 2; C5 Days1, 2, and 8; and days 1 and 2 for any subsequent cycles (Up to 28 months)
Progression-free survival (PFS) in Part 3	From start of extension phase until disease progression, drug discontinuation, withdrawal or death (up to approximately 26 months)	Progression-free survival was defined as the time from first dose of study treatment to the first occurrence of documented disease progression (based on RECIST 1.1 Investigator's assessment) or death from any cause, whichever occurs first.
Change from Baseline in Antidrug Antibody (ADA) to Eciskafusp Alfa	Up to 28 months
Volume of Distribution at Steady-State Conditions (Vss) for Eciskafusp Alfa	Predose, C1 Days 1, 2, 3, 5, 8, 9, 10, 12, 15, 16, 17, and 19; C2 Days 1, 2, 8, 9, 10, 12, 15, and 16; C3 Days 1, 2, 3, and 8; C4 Days 1 and 2; C5 Days1, 2, and 8; and days 1 and 2 for any subsequent cycles (Up to 28 months)
Percentage of Partcipants with ADAs to Eciskafusp Alfa	Up to 28 months
Area Under the Curve (AUC) for Eciskafusp Alfa	Predose, C1 Days 1, 2, 3, 5, 8, 9, 10, 12, 15, 16, 17, and 19; C2 Days 1, 2, 8, 9, 10, 12, 15, and 16; C3 Days 1, 2, 3, and 8; C4 Days 1 and 2; C5 Days1, 2, and 8; and days 1 and 2 for any subsequent cycles (Up to 28 months)
Clearance (CL) for Eciskafusp Alfa	Predose, C1 Days 1, 2, 3, 5, 8, 9, 10, 12, 15, 16, 17, and 19; C2 Days 1, 2, 8, 9, 10, 12, 15, and 16; C3 Days 1, 2, 3, and 8; C4 Days 1 and 2; C5 Days1, 2, and 8; and days 1 and 2 for any subsequent cycles (Up to 28 months)
Change from Baseline in Percentage of Immune Markers	Baseline to End of Treatment (up to approximately 28 months)	Immune markers include PD-1, PD-L1, sCD25, cytokines, etc...
Percentage of Immune Cells with CD8+ PD1+ and CD8+ PD1+ TCF7+ Expression	Baseline
Blood Tumor Mutational Burden	Baseline	Blood tumor mutational burden is defined as the number of genetic mutations per megabase (1,000,000 bases).

Trial Locations

Locations (14)

Cliniques Universitaires St-Luc; 🇧🇪 Bruxelles, Belgium

UZ Leuven Gasthuisberg; 🇧🇪 Leuven, Belgium

Princess Margaret Cancer Center; 🇨🇦 Toronto, Ontario, Canada

Herlev Hospital; 🇩🇰 Herlev, Denmark

Rigshospitalet; 🇩🇰 København Ø, Denmark

Uniwersyteckie Centrum Kliniczne; 🇵🇱 Gda?sk, Poland

Vall d?Hebron Institute of Oncology (VHIO), Barcelona; 🇪🇸 Barcelona, Spain

NKI/AvL; 🇳🇱 Amsterdam, Netherlands

Erasmus MC; 🇳🇱 Rotterdam, Netherlands

Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie; 🇵🇱 Warszawa, Poland

Clinica Universitaria de Navarra; 🇪🇸 Pamplona, Navarra, Spain

Hospital Clinic Barcelona; 🇪🇸 Barcelona, Spain

Hospital del Mar; 🇪🇸 Barcelona, Spain

START Madrid-FJD, Hospital Fundacion Jimenez Diaz; 🇪🇸 Madrid, Spain